Highlights

  • PME shares closed at $193.43, up 0.96% on 24 August 2026
  • Company delivered another record FY2026 performance
  • New US$25 million contract announced in August, expanding the long-term contract base
  • Continued Investment in artificial intelligence for medical-image interpretation

Pro Medicus Ltd (ASX:PME) shares closed at $193.43, up 0.96% on 24 August 2026. The stock remains a focal point for investors weighing whether to add exposure, given the medical-imaging software company's expanding contract base and growing presence within major US healthcare institutions.

About Pro Medicus Ltd

Pro Medicus Ltd is an Australian healthcare technology company specialising in medical-imaging software, best known for its Visage imaging platform used by radiology departments and healthcare institutions to view, analyse and manage diagnostic images. The company's software is designed to improve the efficiency and accuracy of medical-image interpretation, supporting radiologists in delivering faster and more reliable diagnoses. Pro Medicus has built its Business model around long-term contracts with major healthcare providers, particularly within the United States, where its Visage platform has gained significant traction among large hospital systems and imaging networks. This contract-based, recurring-revenue model provides strong visibility over future Earnings and has supported the company's consistently high margins and substantial cash generation. As healthcare providers increasingly seek to modernise their imaging infrastructure and adopt cloud-based and AI-enhanced diagnostic tools, Pro Medicus has positioned itself as a leading provider of enterprise imaging solutions, translating this Demand into sustained Revenue growth over an extended period.

Key Developments

Pro Medicus has delivered another record FY2026 performance, reinforcing the strength of its medical-imaging software business and extending a multi-year track record of consistent growth. The company continues to expand its long-term contract base, with recent attention focused on a new US$25 million contract announced in August, a significant addition that further strengthens the company's Recurring Revenue pipeline. Its Visage imaging platform is increasingly being adopted by major US healthcare institutions, supporting ongoing recurring revenue growth as more large-scale health systems transition to the platform for their enterprise imaging needs. Pro Medicus is also investing in artificial intelligence capabilities designed to improve medical-image interpretation and workflow efficiency, an initiative that positions the company to capture additional value from the growing role of AI within diagnostic radiology. The latest results reinforce strong growth, high margins and substantial cash generation, characteristics that have consistently underpinned the investment case for Pro Medicus. However, valuation remains a key consideration for investors, given the premium multiple at which the stock trades relative to broader healthcare technology peers, reflecting the market's high expectations for continued execution and growth.

Conclusion

Pro Medicus's record FY2026 result and the addition of a new US$25 million contract underscore the continued strength of its Visage imaging platform and its growing footprint within major US healthcare institutions. With ongoing investment in artificial intelligence and a consistently expanding recurring revenue base, the company remains well positioned for further growth. As with many high-performing growth stocks, valuation will remain an important Factor for investors to weigh against the company's strong track record of execution.